Haitai Bio invests 62.01 million yuan to acquire a 23% stake in Beijing Shadong to strengthen its innovative drug development.

Changjiang Business Daily ● Changjiang Business Reporter Liu Qianwen

Haitai Biotech (300683.SZ) “steps into” Beijing Shadong, adding a new player to its biopharmaceutical portfolio.

Recently, Haitai Biotech announced the progress of its external investment, stating that the transaction to acquire a 23.0816% stake in Beijing Shadong Biotechnology Co., Ltd. (hereinafter “Beijing Shadong”) for 62.019 million yuan has been completed and registered with the industrial and commercial authorities. This registration marks the culmination of Haitai Biotech’s twelve-year equity acquisition plan, increasing its ownership in Beijing Shadong to 98.84%, nearly full ownership, further strengthening its control over the core innovative drug asset CPT (a recombinant conformational human tumor necrosis factor-related apoptosis-inducing ligand).

Beijing Shadong’s business registration update completed

According to Haitai Biotech’s March 19, 2026, announcement on the progress of its external investments, the core of this transaction is Haitai Biotech using its own funds of 62.019 million yuan to acquire the 23.0816% equity held by Junhe Enterprise Limited, Zhu Dongmei, Yang Shifang, Cui Junseng, SHA BINGDONG, and We Keli.

This transaction is not isolated; its legal origin traces back to 2014. The announcement clearly states that as early as December 8, 2014, Haitai Biotech signed a “Share Purchase Agreement” with multiple parties including Junhe Enterprise Limited and Zhongguancun Development Group Co., Ltd. The agreement set a long-term trigger clause: within two years after the official market launch of Beijing Shadong’s national Class I new drug, “recombinant conformational human tumor necrosis factor-related apoptosis-inducing ligand,” Haitai Biotech would purchase the relevant shares as stipulated. The signing of this agreement clearly indicates that Haitai Biotech had already included Beijing Shadong and its core R&D product CPT into its strategic vision eleven years ago, pre-locking its investment rights.

In February 2026, Haitai Biotech officially signed the “Share Transfer Agreement” with the transferor, completing the legal documentation of the transaction. Subsequently, Beijing Shadong quickly completed the necessary business registration changes. Recently, the Market Supervision Administration of Mentougou District, Beijing, issued a new business license for Beijing Shadong, marking the completion of all legal and administrative procedures related to the share transfer. Haitai Biotech is now a shareholder holding 98.84% of Beijing Shadong. According to the latest business registration information, Beijing Shadong was established on May 17, 2001, with Chen Ya as legal representative, a registered capital of 22.9388 million yuan, focusing on the development, technical services, and transfer of biomedical and medical device technologies.

Expanding product pipeline

“Class I new drug” is the highest classification in China’s drug review system for innovative medicines, indicating that the drug has not been marketed domestically or internationally and has a novel chemical structure or biological product. CPT, as a conformational variant of “tumor necrosis factor-related apoptosis-inducing ligand,” aims to specifically induce apoptosis in tumor cells, representing a key research direction in targeted cancer therapy. Although the announcement did not disclose the specific R&D stage, indications, or the exact timeline and data for market launch, the trigger condition (“within two years after official market launch”) conveys a critical message: the new CPT drug has achieved a significant milestone from development to commercialization and has officially entered the market.

Haitai Biotech’s main business involves the R&D, production, and sales of biopharmaceuticals. This acquisition is a strategic implementation that helps enrich and expand its product pipeline, especially in innovative cancer treatments. By holding equity in Beijing Shadong, Haitai Biotech gains access to a national Class I new drug project that has already entered commercialization, which could bring long-term profit growth and enhance the company’s recognition and valuation in the innovative drug sector of the capital market. Additionally, the announcement emphasizes that the funding for this acquisition comes from “own funds,” reflecting the company’s stable financial position.

Gaining support from a listed company also provides Beijing Shadong with more sufficient capital backing and broader commercialization platform resources. This can accelerate the market penetration of CPT, the research and development of subsequent indications, and production scale expansion, positively impacting the lifecycle management of this innovative drug.

Editor: ZB

Massive information, precise interpretation, all on Sina Finance APP